PETACH TIKVA, Israel, Aug. 30, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Phase 2 clinical data and animal study data for D-PLEX100 in surgical trauma injuries will be highlighted in a podium presentation at the 2022 Military Health System Research Symposium (MHSRS) being held on September 12-15, 2022, at the Gaylord Palms Resort and Convention Center, Kissimmee, Florida.
The 2022 Military Health System Research Symposium:
||D-PLEX100, a doxycycline releasing antimicrobial product for surgical site wounds, reduces surgical site infection rates and drug resistant-bacteria in surgical trauma injuries.
||Noam Emanuel, PhD, Co-Founder and Chief Scientific Officer, PolyPid.
||Monday, September 12, 2022